Exploring biomarkers to predict tumor response to radiotherapy
Official title: Exploration of Potential Biomarkers to Predict Tumor Response to Radiotherapy in Patients With Solid Tumors
Run by Shantou University Medical College · NCT03744819 · Data updated 2026-11-12
This study is trying to find markers in tumors and blood that can help predict how well solid tumors will respond to radiotherapy in patients who need this treatment.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Shantou University Medical College Academic / other |
| Drugs / interventions | immunotherapy, radiation |
| Locations | 1 site (Shantou, Guangdong) |
| Status | Recruiting |
| Started | October 29, 2018 |
| Main results expected | November 30, 2025 |
| Study ends | November 30, 2026 |
| Registry record updated | February 6, 2024 |
| Trial ID | NCT03744819 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with pathologically confirmed solid tumors who are scheduled for radiotherapy or surgery and can provide informed consent.
✕Probably not a fit
Patients with a history of autoimmune diseases, prior immunotherapy, or contraindications for biopsy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify potential biomarkers that can predict how solid tumors respond to radiotherapy. Patients with pathologically confirmed solid tumors requiring radiotherapy or surgery will be recruited, and tumor samples will be collected to establish baseline biomarker status. Additionally, blood samples and microbiota will be collected before and after surgery, as well as during the course of radiotherapy for those patients. The biological specimens will be analyzed to assess tumor phenotypes and explore biomarkers that could indicate therapeutic outcomes and prognosis.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment plans for patients with solid tumors, improving their therapeutic outcomes.
How similar studies have gone: While the exploration of biomarkers in relation to tumor response is a growing field, this specific approach may offer novel insights into solid tumors and their treatment responses.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathological proven diagnosis of solid tumors * Tumor accessible for biopsy during the course of radiotherapy or tumor samples could be obtained via surgery * Patient must provide study-specific informed consent prior to study entry Exclusion Criteria: * History of autoimmune diseases * History of immunotherapy * Prior radiation therapy that would result in overlap of planned radiation therapy fields * Will receive immunotherapy during the course of radiotherapy * Contraindications for biopsy, such as high bleeding risk
Where it's running
-
Cancer Hospital, Shantou University Medical College
Shantou, Guangdong, China Recruiting
Study contacts
- Principal investigator: Chuangzhen Chen, MD — Affiliated Cancer Hospital of Shantou University Medical College
- Study coordinator: Chuangzhen Chen, MD
- Email: stccz@139.com
- Phone: +86 13923995569
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BA1203 in advanced solid tumors: safety and early signs of activity
This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
REC-7735 for PIK3CA-H1047R-mutant solid tumors
This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.
-
Preferences of physicians and patients for cell therapies in advanced solid tumors
This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.
-
HP007 monotherapy for relapsed or advanced solid tumors
This study tests HP007 as a standalone treatment in adults with hard-to-treat solid tumors to see if it is safe and tolerable and to look for early signs of activity.
-
ONO-7429 in advanced or recurrent solid tumors
This small early-phase study tests whether ONO-7429 is tolerable and safe in adults with unresectable advanced or recurrent solid tumors who have tried other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.